Opinion

Video

Cyclosporine Ophthalmic Solution for Inflammatory Dry Eye

Author(s):

Alice Epitropoulos, MD,Laura M. Periman, MD

Dry eye experts discuss Cyclosporine ophthalmic solution.

Video content above is prompted by the following question(s):

1. Cyclosporine ophthalmic solution, 0.1% (VEVYE)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment
May 14th 2025

EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Palatin releases updated results from responder analyses of phase 3 MELODY-1 trial in dry eye
April 29th 2025

Palatin releases updated results from responder analyses of phase 3 MELODY-1 trial in dry eye

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye
April 20th 2025

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye

Harrow expands VEVYE Access for All program to Klarity-C patients
April 11th 2025

Harrow expands VEVYE Access for All program to Klarity-C patients

© 2025 MJH Life Sciences

All rights reserved.